APO Research
Talk to an analyst

APO RESEARCH · REPORT

Vaccine

A vaccine is a biological preparation that provides active acquired immunity to a particular disease. A vaccine typically contains an agent that resembles a disease-causing microorganism and is often made from weakened or killed forms of the microbe, its toxins or one of its surface proteins. The agent stimulates the body's immune system to recognize the agent as a threat, destroy it, and keep a record of it so that the immune system can more easily recognize and destroy any of these microorganisms that it later encounters. Vaccines can be prophylactic (example: to prevent or ameliorate the effects of a future infection by any natural or "wild" pathogen), or therapeutic (e.g., vaccines against cancer are being investigated).

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

A vaccine is a biological preparation that provides active acquired immunity to a particular disease. A vaccine typically contains an agent that resembles a disease-causing microorganism and is often made from weakened or killed forms of the microbe, its toxins or one of its surface proteins. The agent stimulates the body's immune system to recognize the agent as a threat, destroy it, and keep a record of it so that the immune system can more easily recognize and destroy any of these microorganisms that it later encounters. Vaccines can be prophylactic (example: to prevent or ameliorate the effects of a future infection by any natural or "wild" pathogen), or therapeutic (e.g., vaccines against cancer are being investigated).

Selected research

Market Outlook & Growth Opportunities

Global Vaccine Market Outlook and Growth Opportunities 2026

2 January 2026217 pages

Choose your research edition.

Industry ResearchVaccine Industry Research Report 2026137 pages · $2,950 USDIndustry Growth & TrendsGlobal Vaccine Industry Growth and Trends Forecast to 2032124 pages · $3,450 USDMarket StructureGlobal Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Vaccine Market Outlook and Growth Opportunities 2026217 pages · $4,250 USDMarket Analysis & ForecastGlobal Vaccine Market Analysis and Forecast 2026-2032219 pages · $4,950 USD

Market perspective

A vaccine is a biological preparation that provides active acquired immunity to a particular disease. A vaccine typically contains an agent that resembles a disease-causing microorganism and is often made from weakened or killed forms of the microbe, its toxins or one of its surface proteins. The agent stimulates the body's immune system to recognize the agent as a threat, destroy it, and keep a record of it so that the immune system can more easily recognize and destroy any of these microorganisms that it later encounters. Vaccines can be prophylactic (example: to prevent or ameliorate the effects of a future infection by any natural or "wild" pathogen), or therapeutic (e.g., vaccines against cancer are being investigated).

The global Vaccine market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Europe market for Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Asia Pacific market for Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Vaccine market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Vaccine market include AstraZeneca, BioNTech, Boehringer-Ingelheim, CCBIO, CSL, CureVac, Elanco, GSK and Hulan Bio, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Vaccine market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Vaccine and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Vaccine revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Vaccine market.

Vaccine Segment by Company

AstraZeneca

BioNTech

Boehringer-Ingelheim

CCBIO

CSL

CureVac

Elanco

GSK

Hulan Bio

Indian Immunologicals

Merck

Minhai Biotechnology

Mitsubishi Tanabe Pharma

Moderna Therapeutics

Mylan

Plumbline Life Sciences

Sanofi

Translate Bio

Walvax Biotechnology

Wuhan Institute of Biological Products

Zoties

Vaccine Segment by Type

Varicella Vaccine

Influenza Vaccine

Polio Vaccine

Hepatitis A Vaccine

Rabies Vaccine

BCG Vaccine

Hepatitis B

Pertussis, Diphtheria, Tetanus

Pneumococcal

Others

Vaccine Segment by Application

For Adult

For Child

Vaccine Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Vaccine status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Vaccine key companies, revenue, market share, and recent developments.

3. To split the Vaccine breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Vaccine market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Vaccine significant trends, drivers, influence factors in global and regions.

6. To analyze Vaccine competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Vaccine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Vaccine industry.

Chapter 3: Detailed analysis of Vaccine company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Vaccine in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Vaccine Industry Trends Table 2. Vaccine Industry Drivers Table 3. Vaccine Industry Opportunities and Challenges Table 4. Vaccine Industry Restraints Table 5. Global Vaccine Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Vaccine Revenue Share by Company (2021-2026) Table 7. Global Vaccine Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Vaccine Key Company Manufacturing Base & Headquarters Table 9. Global Vaccine Company, Product Type & Application Table 10. Global Vaccine Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Varicella Vaccine Table 15. Significant Companies of Influenza Vaccine Table 16. Significant Companies of Polio Vaccine Table 17. Significant Companies of Hepatitis A Vaccine Table 18. Significant Companies of Rabies Vaccine Table 19. Significant Companies of BCG Vaccine Table 20. Significant Companies of Hepatitis B Table 21. Significant Companies of Pertussis, Diphtheria, Tetanus Table 22. Significant Companies of Pneumococcal Table 23. Significant Companies of Others Table 24. Global Vaccine Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Vaccine Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Vaccine Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Vaccine Sales Value Share by Type (2021-2026) Table 28. Global Vaccine Sales Value Share by Type (2027-2032) Table 29. Significant Companies of For Adult Table 30. Significant Companies of For Child Table 31. Global Vaccine Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Vaccine Sales Value by Application (2021-2026) & (US$ Million) Table 33. Global Vaccine Sales Value by Application (2027-2032) & (US$ Million) Table 34. Global Vaccine Sales Value Share by Application (2021-2026) Table 35. Global Vaccine Sales Value Share by Application (2027-2032) Table 36. Global Vaccine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Vaccine Sales Value by Region (2021-2026) & (US$ Million) Table 38. Global Vaccine Sales Value Share by Region (2021-2026) Table 39. Global Vaccine Sales Value by Region (2027-2032) & (US$ Million) Table 40. Global Vaccine Sales Value Share by Region (2027-2032) Table 41. Global Vaccine Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 42. Global Vaccine Sales Value by Country (2021-2026) & (US$ Million) Table 43. Global Vaccine Sales Value Market Share by Country (2021-2026) Table 44. Global Vaccine Sales Value by Country (2027-2032) & (US$ Million) Table 45. Global Vaccine Sales Value Market Share by Country (2027-2032) Table 46. AstraZeneca Company Information Table 47. AstraZeneca Business Overview Table 48. AstraZeneca Vaccine Revenue (US$ Million) and Gross Margin (2021-2026) Table 49. AstraZeneca Vaccine Product Portfolio Table 50. AstraZeneca Recent Development Table 51. BioNTech Company Information Table 52. BioNTech Business Overview Table 53. BioNTech Vaccine Revenue (US$ Million) and Gross Margin (2021-2026) Table 54. BioNTech Vaccine Product Portfolio Table 55. BioNTech Recent Development Table 56. Boehringer-Ingelheim Company Information Table 57. Boehringer-Ingelheim Business Overview Table 58. Boehringer-Ingelheim Vaccine Revenue (US$ Million) and Gross Margin (2021-2026) Table 59. Boehringer-Ingelheim Vaccine Product Portfolio Table 60. Boehringer-Ingelheim Recent Development Table 61. CCBIO Company Information Table 62. CCBIO Business Overview Table 63. CCBIO Vaccine Revenue (US$ Million) and Gross Margin (2021-2026) Table 64. CCBIO Vaccine Product Portfolio Table 65. CCBIO Recent Development Table 66. CSL Company Information Table 67. CSL Business Overview Table 68. CSL Vaccine Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. CSL Vaccine Product Portfolio Table 70. CSL Recent Development Table 71. CureVac Company Information Table 72. CureVac Business Overview Table 73. CureVac Vaccine Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. CureVac Vaccine Product Portfolio Table 75. CureVac Recent Development Table 76. Elanco Company Information Table 77. Elanco Business Overview Table 78. Elanco Vaccine Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. Elanco Vaccine Product Portfolio Table 80. Elanco Recent Development Table 81. GSK Company Information Table 82. GSK Business Overview Table 83. GSK Vaccine Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. GSK Vaccine Product Portfolio Table 85. GSK Recent Development Table 86. Hulan Bio Company Information Table 87. Hulan Bio Business Overview Table 88. Hulan Bio Vaccine Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. Hulan Bio Vaccine Product Portfolio Table 90. Hulan Bio Recent Development Table 91. Indian Immunologicals Company Information Table 92. Indian Immunologicals Business Overview Table 93. Indian Immunologicals Vaccine Revenue (US$ Million) and Gross Margin (2021-2026) Table 94. Indian Immunologicals Vaccine Product Portfolio Table 95. Indian Immunologicals Recent Development Table 96. Merck Company Information Table 97. Merck Business Overview Table 98. Merck Vaccine Sales (M Dose), Value (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 99. Merck Vaccine Product Portfolio Table 100. Merck Recent Development Table 101. Minhai Biotechnology Company Information Table 102. Minhai Biotechnology Business Overview Table 103. Minhai Biotechnology Vaccine Sales (M Dose), Value (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 104. Minhai Biotechnology Vaccine Product Portfolio Table 105. Minhai Biotechnology Recent Development Table 106. Mitsubishi Tanabe Pharma Company Information Table 107. Mitsubishi Tanabe Pharma Business Overview Table 108. Mitsubishi Tanabe Pharma Vaccine Sales (M Dose), Value (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 109. Mitsubishi Tanabe Pharma Vaccine Product Portfolio Table 110. Mitsubishi Tanabe Pharma Recent Development Table 111. Moderna Therapeutics Company Information Table 112. Moderna Therapeutics Business Overview Table 113. Moderna Therapeutics Vaccine Sales (M Dose), Value (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 114. Moderna Therapeutics Vaccine Product Portfolio Table 115. Moderna Therapeutics Recent Development Table 116. Mylan Company Information Table 117. Mylan Business Overview Table 118. Mylan Vaccine Sales (M Dose), Value (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 119. Mylan Vaccine Product Portfolio Table 120. Mylan Recent Development Table 121. Plumbline Life Sciences Company Information Table 122. Plumbline Life Sciences Business Overview Table 123. Plumbline Life Sciences Vaccine Sales (M Dose), Value (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 124. Plumbline Life Sciences Vaccine Product Portfolio Table 125. Plumbline Life Sciences Recent Development Table 126. Sanofi Company Information Table 127. Sanofi Business Overview Table 128. Sanofi Vaccine Sales (M Dose), Value (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 129. Sanofi Vaccine Product Portfolio Table 130. Sanofi Recent Development Table 131. Translate Bio Company Information Table 132. Translate Bio Business Overview Table 133. Translate Bio Vaccine Sales (M Dose), Value (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 134. Translate Bio Vaccine Product Portfolio Table 135. Translate Bio Recent Development Table 136. Walvax Biotechnology Company Information Table 137. Walvax Biotechnology Business Overview Table 138. Walvax Biotechnology Vaccine Sales (M Dose), Value (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 139. Walvax Biotechnology Vaccine Product Portfolio Table 140. Walvax Biotechnology Recent Development Table 141. Wuhan Institute of Biological Products Company Information Table 142. Wuhan Institute of Biological Products Business Overview Table 143. Wuhan Institute of Biological Products Vaccine Sales (M Dose), Value (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 144. Wuhan Institute of Biological Products Vaccine Product Portfolio Table 145. Wuhan Institute of Biological Products Recent Development Table 146. Zoties Company Information Table 147. Zoties Business Overview Table 148. Zoties Vaccine Sales (M Dose), Value (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026) Table 149. Zoties Vaccine Product Portfolio Table 150. Zoties Recent Development Table 151. Research Programs/Design for This Report Table 152. Authors List of This Report Table 153. Secondary Sources Table 154. Primary Sources List of Figures Figure 1. Vaccine Product Image Figure 2. Global Vaccine Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Vaccine Market Size (2021-2032) & (US$ Million) Figure 4. Global Vaccine Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Varicella Vaccine Image Figure 8. Influenza Vaccine Image Figure 9. Polio Vaccine Image Figure 10. Hepatitis A Vaccine Image Figure 11. Rabies Vaccine Image Figure 12. BCG Vaccine Image Figure 13. Hepatitis B Image Figure 14. Pertussis, Diphtheria, Tetanus Image Figure 15. Pneumococcal Image Figure 16. Others Image Figure 17. Global Vaccine Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Vaccine Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global Vaccine Sales Value Share by Type (2021-2032) Figure 20. For Adult Image Figure 21. For Child Image Figure 22. Global Vaccine Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global Vaccine Sales Value Share 2021 VS 2025 VS 2032 Figure 24. Global Vaccine Sales Value Share by Application (2021-2032) Figure 25. Global Vaccine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 26. Global Vaccine Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 27. North America Vaccine Sales Value (2021-2032) & (US$ Million) Figure 28. North America Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 29. Europe Vaccine Sales Value (2021-2032) & (US$ Million) Figure 30. Europe Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 31. Asia-Pacific Vaccine Sales Value (2021-2032) & (US$ Million) Figure 32. Asia-Pacific Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 33. South America Vaccine Sales Value (2021-2032) & (US$ Million) Figure 34. South America Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Middle East & Africa Vaccine Sales Value (2021-2032) & (US$ Million) Figure 36. Middle East & Africa Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 37. USA Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 38. USA Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 39. USA Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 40. Canada Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. Canada Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. Canada Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Mexico Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Mexico Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Mexico Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Germany Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Germany Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Germany Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. France Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. France Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. France Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. U.K. Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. U.K. Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. U.K. Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Italy Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Italy Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Italy Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Spain Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Spain Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Spain Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Russia Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Russia Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Russia Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Netherlands Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Netherlands Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Netherlands Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Nordic Countries Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Nordic Countries Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Nordic Countries Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. China Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. China Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. China Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. Japan Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. Japan Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. Japan Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. South Korea Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. South Korea Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. South Korea Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. India Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. India Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. India Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Australia Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Australia Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Australia Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Southeast Asia Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Southeast Asia Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Southeast Asia Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Brazil Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Brazil Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Brazil Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Argentina Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Argentina Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Argentina Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Chile Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Chile Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Chile Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Colombia Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Colombia Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Colombia Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Peru Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Peru Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Peru Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Saudi Arabia Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Saudi Arabia Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Saudi Arabia Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Israel Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Israel Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Israel Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. UAE Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. UAE Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. UAE Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Turkey Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Turkey Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Turkey Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Iran Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Iran Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Iran Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Egypt Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Egypt Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Egypt Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Years Considered Figure 122. Research Process Figure 123. Key Executives Interviewed

Scope & coverage.

Types
  • Varicella Vaccine
  • Influenza Vaccine
  • Polio Vaccine
  • Hepatitis A Vaccine
  • Rabies Vaccine
  • BCG Vaccine
  • Hepatitis B
  • Pertussis, Diphtheria, Tetanus
  • Pneumococcal
  • Others
Applications
  • For Adult
  • For Child
Companies covered
  • AstraZeneca
  • BioNTech
  • Boehringer-Ingelheim
  • CCBIO
  • CSL
  • CureVac
  • Elanco
  • GSK
  • Hulan Bio
  • Indian Immunologicals
  • Merck
  • Minhai Biotechnology
  • Mitsubishi Tanabe Pharma
  • Moderna Therapeutics
  • Mylan
  • Plumbline Life Sciences
  • Sanofi
  • Translate Bio
  • Walvax Biotechnology
  • Wuhan Institute of Biological Products
  • Zoties

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Vaccine Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Vaccine Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Vaccine Market Dynamics
  1. 2.1 Vaccine Industry Trends
  2. 2.2 Vaccine Industry Drivers
  3. 2.3 Vaccine Industry Opportunities and Challenges
  4. 2.4 Vaccine Industry Restraints
3 Vaccine Market by Company
  1. 3.1 Global Vaccine Company Revenue Ranking in 2025
  2. 3.2 Global Vaccine Revenue by Company (2021-2026)
  3. 3.3 Global Vaccine Company Ranking (2024-2026)
  4. 3.4 Global Vaccine Company Manufacturing Base and Headquarters
  5. 3.5 Global Vaccine Company Product Type and Application
  6. 3.6 Global Vaccine Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Vaccine Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Vaccine Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Vaccine Market by Type
  1. 4.1 Vaccine Type Introduction
  2. 4.1.1 Varicella Vaccine
  3. 4.1.2 Influenza Vaccine
  4. 4.1.3 Polio Vaccine
  5. 4.1.4 Hepatitis A Vaccine
  6. 4.1.5 Rabies Vaccine
  7. 4.1.6 BCG Vaccine
  8. 4.1.7 Hepatitis B
  9. 4.1.8 Pertussis, Diphtheria, Tetanus
  10. 4.1.9 Pneumococcal
  11. 4.1.10 Others
  12. 4.2 Global Vaccine Sales Value by Type
  13. 4.2.1 Global Vaccine Sales Value by Type (2021 VS 2025 VS 2032)
  14. 4.2.2 Global Vaccine Sales Value by Type (2021-2032)
  15. 4.2.3 Global Vaccine Sales Value Share by Type (2021-2032)
5 Vaccine Market by Application
  1. 5.1 Vaccine Application Introduction
  2. 5.1.1 For Adult
  3. 5.1.2 For Child
  4. 5.2 Global Vaccine Sales Value by Application
  5. 5.2.1 Global Vaccine Sales Value by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Vaccine Sales Value by Application (2021-2032)
  7. 5.2.3 Global Vaccine Sales Value Share by Application (2021-2032)
6 Vaccine Regional Value Analysis
  1. 6.1 Global Vaccine Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Vaccine Sales Value by Region (2021-2032)
  3. 6.2.1 Global Vaccine Sales Value by Region: 2021-2026
  4. 6.2.2 Global Vaccine Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Vaccine Sales Value (2021-2032)
  7. 6.3.2 North America Vaccine Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Vaccine Sales Value (2021-2032)
  10. 6.4.2 Europe Vaccine Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Vaccine Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Vaccine Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Vaccine Sales Value (2021-2032)
  16. 6.6.2 South America Vaccine Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Vaccine Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Vaccine Sales Value Share by Country, 2025 VS 2032
7 Vaccine Country-level Value Analysis
  1. 7.1 Global Vaccine Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Vaccine Sales Value by Country (2021-2032)
  3. 7.2.1 Global Vaccine Sales Value by Country (2021-2026)
  4. 7.2.2 Global Vaccine Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Vaccine Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Vaccine Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Vaccine Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Vaccine Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Vaccine Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Vaccine Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Vaccine Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Vaccine Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Vaccine Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Vaccine Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Vaccine Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Vaccine Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Vaccine Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Vaccine Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Vaccine Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Vaccine Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Vaccine Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Vaccine Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Vaccine Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Vaccine Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Vaccine Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Vaccine Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Vaccine Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Vaccine Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Vaccine Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Vaccine Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Vaccine Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Vaccine Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Vaccine Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Vaccine Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Vaccine Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Vaccine Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Vaccine Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Vaccine Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Vaccine Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Vaccine Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Vaccine Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Vaccine Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Vaccine Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Vaccine Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Vaccine Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Vaccine Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Vaccine Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Vaccine Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Vaccine Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Vaccine Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Vaccine Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Vaccine Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Vaccine Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Vaccine Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Vaccine Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Vaccine Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Vaccine Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Vaccine Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Vaccine Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Vaccine Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Vaccine Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Vaccine Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Vaccine Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Vaccine Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Vaccine Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Vaccine Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Vaccine Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Vaccine Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Vaccine Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Vaccine Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Vaccine Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Vaccine Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Vaccine Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Vaccine Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Vaccine Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Vaccine Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Vaccine Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Vaccine Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Vaccine Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Vaccine Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Vaccine Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Vaccine Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Vaccine Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Vaccine Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Vaccine Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Vaccine Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Vaccine Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Vaccine Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 AstraZeneca
  2. 8.1.1 AstraZeneca Company Information
  3. 8.1.2 AstraZeneca Business Overview
  4. 8.1.3 AstraZeneca Vaccine Revenue and Gross Margin (2021-2026)
  5. 8.1.4 AstraZeneca Vaccine Product Portfolio
  6. 8.1.5 AstraZeneca Recent Developments
  7. 8.2 BioNTech
  8. 8.2.1 BioNTech Company Information
  9. 8.2.2 BioNTech Business Overview
  10. 8.2.3 BioNTech Vaccine Revenue and Gross Margin (2021-2026)
  11. 8.2.4 BioNTech Vaccine Product Portfolio
  12. 8.2.5 BioNTech Recent Developments
  13. 8.3 Boehringer-Ingelheim
  14. 8.3.1 Boehringer-Ingelheim Company Information
  15. 8.3.2 Boehringer-Ingelheim Business Overview
  16. 8.3.3 Boehringer-Ingelheim Vaccine Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Boehringer-Ingelheim Vaccine Product Portfolio
  18. 8.3.5 Boehringer-Ingelheim Recent Developments
  19. 8.4 CCBIO
  20. 8.4.1 CCBIO Company Information
  21. 8.4.2 CCBIO Business Overview
  22. 8.4.3 CCBIO Vaccine Revenue and Gross Margin (2021-2026)
  23. 8.4.4 CCBIO Vaccine Product Portfolio
  24. 8.4.5 CCBIO Recent Developments
  25. 8.5 CSL
  26. 8.5.1 CSL Company Information
  27. 8.5.2 CSL Business Overview
  28. 8.5.3 CSL Vaccine Revenue and Gross Margin (2021-2026)
  29. 8.5.4 CSL Vaccine Product Portfolio
  30. 8.5.5 CSL Recent Developments
  31. 8.6 CureVac
  32. 8.6.1 CureVac Company Information
  33. 8.6.2 CureVac Business Overview
  34. 8.6.3 CureVac Vaccine Revenue and Gross Margin (2021-2026)
  35. 8.6.4 CureVac Vaccine Product Portfolio
  36. 8.6.5 CureVac Recent Developments
  37. 8.7 Elanco
  38. 8.7.1 Elanco Company Information
  39. 8.7.2 Elanco Business Overview
  40. 8.7.3 Elanco Vaccine Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Elanco Vaccine Product Portfolio
  42. 8.7.5 Elanco Recent Developments
  43. 8.8 GSK
  44. 8.8.1 GSK Company Information
  45. 8.8.2 GSK Business Overview
  46. 8.8.3 GSK Vaccine Revenue and Gross Margin (2021-2026)
  47. 8.8.4 GSK Vaccine Product Portfolio
  48. 8.8.5 GSK Recent Developments
  49. 8.9 Hulan Bio
  50. 8.9.1 Hulan Bio Company Information
  51. 8.9.2 Hulan Bio Business Overview
  52. 8.9.3 Hulan Bio Vaccine Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Hulan Bio Vaccine Product Portfolio
  54. 8.9.5 Hulan Bio Recent Developments
  55. 8.10 Indian Immunologicals
  56. 8.10.1 Indian Immunologicals Company Information
  57. 8.10.2 Indian Immunologicals Business Overview
  58. 8.10.3 Indian Immunologicals Vaccine Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Indian Immunologicals Vaccine Product Portfolio
  60. 8.10.5 Indian Immunologicals Recent Developments
  61. 8.11 Merck
  62. 8.11.1 Merck Company Information
  63. 8.11.2 Merck Business Overview
  64. 8.11.3 Merck Vaccine Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Merck Vaccine Product Portfolio
  66. 8.11.5 Merck Recent Developments
  67. 8.12 Minhai Biotechnology
  68. 8.12.1 Minhai Biotechnology Company Information
  69. 8.12.2 Minhai Biotechnology Business Overview
  70. 8.12.3 Minhai Biotechnology Vaccine Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Minhai Biotechnology Vaccine Product Portfolio
  72. 8.12.5 Minhai Biotechnology Recent Developments
  73. 8.13 Mitsubishi Tanabe Pharma
  74. 8.13.1 Mitsubishi Tanabe Pharma Company Information
  75. 8.13.2 Mitsubishi Tanabe Pharma Business Overview
  76. 8.13.3 Mitsubishi Tanabe Pharma Vaccine Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Mitsubishi Tanabe Pharma Vaccine Product Portfolio
  78. 8.13.5 Mitsubishi Tanabe Pharma Recent Developments
  79. 8.14 Moderna Therapeutics
  80. 8.14.1 Moderna Therapeutics Company Information
  81. 8.14.2 Moderna Therapeutics Business Overview
  82. 8.14.3 Moderna Therapeutics Vaccine Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Moderna Therapeutics Vaccine Product Portfolio
  84. 8.14.5 Moderna Therapeutics Recent Developments
  85. 8.15 Mylan
  86. 8.15.1 Mylan Company Information
  87. 8.15.2 Mylan Business Overview
  88. 8.15.3 Mylan Vaccine Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Mylan Vaccine Product Portfolio
  90. 8.15.5 Mylan Recent Developments
  91. 8.16 Plumbline Life Sciences
  92. 8.16.1 Plumbline Life Sciences Company Information
  93. 8.16.2 Plumbline Life Sciences Business Overview
  94. 8.16.3 Plumbline Life Sciences Vaccine Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Plumbline Life Sciences Vaccine Product Portfolio
  96. 8.16.5 Plumbline Life Sciences Recent Developments
  97. 8.17 Sanofi
  98. 8.17.1 Sanofi Company Information
  99. 8.17.2 Sanofi Business Overview
  100. 8.17.3 Sanofi Vaccine Revenue and Gross Margin (2021-2026)
  101. 8.17.4 Sanofi Vaccine Product Portfolio
  102. 8.17.5 Sanofi Recent Developments
  103. 8.18 Translate Bio
  104. 8.18.1 Translate Bio Company Information
  105. 8.18.2 Translate Bio Business Overview
  106. 8.18.3 Translate Bio Vaccine Revenue and Gross Margin (2021-2026)
  107. 8.18.4 Translate Bio Vaccine Product Portfolio
  108. 8.18.5 Translate Bio Recent Developments
  109. 8.19 Walvax Biotechnology
  110. 8.19.1 Walvax Biotechnology Company Information
  111. 8.19.2 Walvax Biotechnology Business Overview
  112. 8.19.3 Walvax Biotechnology Vaccine Revenue and Gross Margin (2021-2026)
  113. 8.19.4 Walvax Biotechnology Vaccine Product Portfolio
  114. 8.19.5 Walvax Biotechnology Recent Developments
  115. 8.20 Wuhan Institute of Biological Products
  116. 8.20.1 Wuhan Institute of Biological Products Company Information
  117. 8.20.2 Wuhan Institute of Biological Products Business Overview
  118. 8.20.3 Wuhan Institute of Biological Products Vaccine Revenue and Gross Margin (2021-2026)
  119. 8.20.4 Wuhan Institute of Biological Products Vaccine Product Portfolio
  120. 8.20.5 Wuhan Institute of Biological Products Recent Developments
  121. 8.21 Zoties
  122. 8.21.1 Zoties Company Information
  123. 8.21.2 Zoties Business Overview
  124. 8.21.3 Zoties Vaccine Revenue and Gross Margin (2021-2026)
  125. 8.21.4 Zoties Vaccine Product Portfolio
  126. 8.21.5 Zoties Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst